Perspective directions in the treatment of polycystic ovary syndrome (literature review)

Close metadata

Recommended articles:

Traumatic damage to the diaphragm in children. Pirogov Russian Journal of Surgery. 2024;(4):64-68

Promising approaches to the pathogenetic therapy of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21

Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68

Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99

Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medicine. 2024;(5):75-80

Our experience in the treatment of congenital nasal median heterotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32

Clinical and anatomical rationale for the effectiveness of treatment of phlegmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25

B vitamins and diseases of the peripheral nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):75-82

Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137

Experience with the use of risdiplam in a familial case of spinal muscular atrophy 5q in patients with a homozygous deletion of the SMN1 gene and the same copy number of the SMN2 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):138-141

Polycystic ovary syndrome (PCOS) is a common disease among women of reproductive age, manifested by a wide range of hormonal and metabolic disorders. Since the exact etiology of PCOS is still unclear, available pharmacotherapy is mainly aimed at relieving symptoms and associated metabolic disorders. With the emergence of new data on the pathogenesis of the syndrome, other treatment methods are being developed. This publication is a review of current and new treatments for women with PCOS. As you know, the symptoms of this disease are very diverse. None of the available pharmacological treatment options can cover the entire spectrum of clinical manifestations observed in women with this pathology. Therefore, treatment must be individualized and adapted to the specific needs of each patient. The article reviews data on the use of various drugs for the correction of metabolic disorders. Information is provided on new approaches to treatment aimed at correcting neurohormonal regulation. Also analyzed are studies devoted to the study of innovative methods of therapy from the perspective of complex mechanisms of control of cellular activity, proliferation, apoptosis, which underlie pathogenesis. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full text of articles. The choice of sources was prioritized for the period from 2017 to 2023, however, the list of references contains several publications dating back to earlier years.

Keywords:

polycystic ovary syndrome

treatment

glucagon-like peptide 1 receptor agonists

orexins

exosomes

Authors:

Absatarova Yu.S.

Endocrinology Research Centre Russia

ORCID: 0000-0003-0696-5367

Evseeva Yu.S.

Endocrinology Research Centre Russia

ORCID: 0009-0007-8189-1384

Andreeva E.N.

Endocrinology Research Centre Russia;
FSBEI HE «Russian University of Medicine" Ministry of Health of Russia

ORCID: 0000-0001-8425-0020

Sheremetyeva E.V.

A.I. Evdokimov Moscow State University of Medicine and Dentistry

ORCID: 0000-0001-7177-0254

Melnichenko G.A.

Endocrinology Research Centre Russia

ORCID: 0000-0002-5634-7877

Received:

07.12.2023

Accepted:

25.02.2024

List of references:

Motlagh Asghari K, Nejadghaderi SA, Alizadeh M, Sanaie S, Sullman MJM, Kolahi AA, Avery J, Safiri S. Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990—2019. Scientific Reports. 2022;12(1):7039. https://doi.org/10.1038/s41598-022-11006-0El
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE; International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome†. Human Reproduction. 2023;38(9):1655-1679. https://doi.org/10.1093/humrep/dead156
Adone A, Fulmali DG. Polycystic Ovarian Syndrome in Adolescents. Cureus. 2023;15(1):e34183. https://doi.org/10.7759/cureus.34183
Chen W, Pang Y. Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites. 2021;11(12):869. https://doi.org/10.3390/metabo11120869
Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. International Journal of Molecular Sciences. 2022;23(8):4110. https://doi.org/10.3390/ijms23084110
Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, Wu D. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sciences. 2019; 228:167-175. https://doi.org/10.1016/j.lfs.2019.04.046
Sindrom polikistoznyh yaichnikov. Klinicheskie rekomendacii. Odobreno Nauchno-prakticheskim Sovetom Ministerstva zdravooxraneniya Rossijskoj Federacii. 2021. Accessed December 12, 2023. (In Russ.). https://minzdrav.samregion.ru/wp-content/uploads/sites/28/2021/07/kr258.pdf
Artymuk NV, Tachkova OA. New about the pathogenesis and treatment of polycystic ovary syndrome. RMZh. Mat’ i ditya. 2021;4(1): 17-22. (In Russ.). https://doi.org/10.32364/2618-8430-2021-4-1-17-22
Grishin II, Chirvon TG, Oguede OR. Current trends in surgical treatment for infertility associated with polycystic ovary syndrome. RMZh. Mat’ i ditya. 2022;5(3):209-214. (In Russ.). https://doi.org/10.32364/2618-8430-2022-5-3-209-214
Il’ina IYu. Specificities of the treatment for polycystic ovary syndrome and metabolic syndrome. RMZh. Mat’ i ditya. 2020;3(4): 254-259. (In Russ.). https://doi.org/10.32364/2618-8430-2020-3-4-254-259
Merviel P, James P, Bouée S, Le Guillou M, Rince C, Nachtergaele C, Kerlan V. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reproductive Health. 2021;18(1):13. https://doi.org/10.1186/s12978-021-01073-3
Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirády P, Ács N, Várbíró S, Horváth EM. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology. 2023;21(1):10. https://doi.org/10.1186/s12958-023-01055-z
Helvaci N, Yildiz BO. Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert opinion on pharmacotherapy. 2023;24(1):105-120. https://doi.org/10.1080/14656566.2022.2108702
Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes, Obesity and Metabolism. 2018;20(1):215-218. https://doi.org/10.1111/dom.13053
Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Archives of Gynecology and Obstetrics. 2016;293(3): 509-515. https://doi.org/10.1007/s00404-015-3976-7
Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine. 2023;12(18):5921. https://doi.org/10.3390/jcm12185921
Khaykina EV, Kozlov SN, Bulygina AA, Ermolenkova EG. Long-Term Efficiency and Safety of Early Combination Therapy with Metformin and Vildagliptin in Patients with Type 2 Diabetes Mellitus. Trudnyi patsient. 2020;18(11-12):24-26. (In Russ.). https://doi.org/10.24411/2074-1995-2020-10078
Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism. 2020;105(1):136-151. https://doi.org/10.1210/clinem/dgz028
Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in Metformin-intolerant obese women with Polycystic ovary syndrome: a pilot randomized study. Endocrine Practice. 2018;24(1):69-77. https://doi.org/10.4158/EP-2017-0027
Jensterle M, Goricar K, Janez A. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. Endocrine Research. 2017;42(4):261-268. https://doi.org/10.1080/07435800.2017.1294602
Salukhov VV, Galstyan GR, Ilyinskaya TA. Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives. Diabetes Mellitus. 2022;25(3):275-287. (In Russ.). https://doi.org/10.14341/DM12855
Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology. 2019; 90(6):805-813. https://doi.org/10.1111/cen.13968
Bays HE, Kozlovski P, Shao Q, Proot P, Keefe D. Licogliflozin, a novel SGLT1 and 2 Inhibitor: body weight effects in a randomized trial in adults with overweight or obesity. Obesity. 2020;28(5): 870-881. https://doi.org/10.1002/oby.22764
Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, Dunschen K, Zakaria M, Huseinovic N, Basson CT, Mahling P, Fuhrer D, Hinder M. Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial. Diabetes, Obesity and Metabolism. 2021;23(11):2595-2599. https://doi.org/10.1111/dom.14495
Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219-230. https://doi.org/10.1007/s40265-019-1057-0
Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism. 2021; 106(10):3019-3033. https://doi.org/10.1210/clinem/dgab408
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders. 2021;12(1):143-157. https://doi.org/10.1007/s13300-020-00981-0
Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update. 2018;24(4):455-467. https://doi.org/10.1093/humupd/dmy007
Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA. Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome. Human Reproduction. 2020;35(6):1421-1431. https://doi.org/10.1093/humrep/deaa104
Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, Serin A, Mungan NO, Cook JR, Imamoglu S, Akalin NS, Yuksel B, O’Rahilly S, Semple RK. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nature Genetics. 2009;41(3):354-358. https://doi.org/10.1038/ng.306
Pinkerton JV, Redick DL, Homewood LN, Kaunitz AM. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms. The Journal of Clinical Endocrinology and Metabolism. 2023;108(11):e1448-e1449. https://doi.org/10.1210/clinem/dgad209
Fraser GL, Obermayer-Pietsch B, Laven J, Griesinger G, Pintiaux A, Timmerman D, Fauser BCJM, Lademacher C, Combalbert J, Hoveyda HR, Ramael S. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism. 2021;106(9):e3519-e3532. https://doi.org/10.1210/clinem/dgab320
Silveyra P, Cataldi NI, Lux-Lantos VA, Libertun C. Role of orexins in the hypothalamic-pituitary-ovarian relationships. Acta Physiologica. 2010;198(3):355-360. https://doi.org/10.1111/j.1748-1716.2009.02049.x
Milbank E, López M. Orexins/Hypocretins: Key Regulators of Energy Homeostasis. Frontiers in Endocrinology. 2019;10:830. https://doi.org/10.3389/fendo.2019.00830
Lainez NM, Coss D. Obesity, Neuroinflammation, and Reproductive Function. Endocrinology. 2019;160(11):2719-2736. https://doi.org/10.1210/en.2019-00487
Mlyczyńska E, Kieżun M, Kurowska P, Dawid M, Pich K, Respekta N, Daudon M, Rytelewska E, Dobrzyń K, Kamińska B, Kamiński T, Smolińska N, Dupont J, Rak A. New Aspects of Corpus Luteum Regulation in Physiological and Pathological Conditions: Involvement of Adipokines and Neuropeptides. Cells. 2022; 11(6):957. https://doi.org/10.3390/cells11060957
Safdar M, Liang A, Rajput SA, Abbas N, Zubair M, Shaukat A, Rehman AU, Jamil H, Guo Y, Ullah F, Yang L. Orexin-A Regulates Follicular Growth, Proliferation, Cell Cycle and Apoptosis in Mouse Primary Granulosa Cells via the AKT/ERK Signaling Pathway. Molecules. 2021;26(18):5635. https://doi.org/10.3390/molecules26185635
Yilmaz E, Celik O, Celik N, Simsek Y, Celik E, Yildirim E. Serum orexin-A (OXA) level decreases in polycystic ovarian syndrome. Gynecological Endocrinology. 2013;29(4):388-390. https://doi.org/10.3109/09513590.2012.754874
Campo A, Dufour S, Rousseau K. Tachykinins, new players in the control of reproduction and food intake: A comparative review in mammals and teleosts. Frontiers in Endocrinology. 2022;13:1056939. https://doi.org/10.3389/fendo.2022.1056939
Lasaga M, Debeljuk L. Tachykinins and the hypothalamo-pituitary-gonadal axis: An update. Peptides. 2011;32(9):1972-1978. https://doi.org/10.1016/j.peptides.2011.07.009
Kouhetsani S, Khazali H, Rajabi-Maham H. Orexin antagonism and substance-P: Effects and interactions on polycystic ovary syndrome in the wistar rats. Journal of Ovarian Research. 2023;16(1):89. https://doi.org/10.1186/s13048-023-01168-4
Liu Y, Chen X, Deng X, Yang F, Zheng J, Zhou T, Xu L, Xie X, Ju Z, Wang B, Zhang C, Zhou Y. Association of NAD+ levels with metabolic disease in a community-based study. Frontiers in Endocrinology. 2023;14:1164788. https://doi.org/10.3389/fendo.2023.1164788
Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196. https://doi.org/10.1038/nature01960
Smith J. Human Sir2 and the ‘silencing’ of p53 activity. Trends in Cell Biology. 2002;12(9):404-406. https://doi.org/10.1016/s0962-8924(02)02342-5
Wang ZH, Bao XG, Hu JJ, Shen SB, Xu GH, Wu YL. Nicotinamide Riboside Enhances Endothelial Precursor Cell Function to Promote Refractory Wound Healing Through Mediating the Sirt1/AMPK Pathway. Frontiers in Pharmacology. 2021;12:671563. https://doi.org/10.3389/fphar.2021.671563
Pavlová S, Klucska K, Vašíček D, Ryban L, Harrath AH, Alwasel SH, Sirotkin AV. The involvement of SIRT1 and transcription factor NF-κB (p50/p65) in regulation of porcine ovarian cell function. Animal Reproduction Science. 2013;140(3-4):180-188. https://doi.org/10.1016/j.anireprosci.2013.06.013
Ji R, Jia F, Chen X, Gao Y, Yang J. Carnosol inhibits KGN cells oxidative stress and apoptosis and attenuates polycystic ovary syndrome phenotypes in mice through Keap1-mediated Nrf2/HO-1 activation. Phytotherapy Research. 2023;37(4):1405-1421. https://doi.org/10.1002/ptr.7749
Liu Q, Kong L, Zhang J, Xu Q, Wang J, Xue Z, Wang J. Involvement of GJA1 and Gap Junctional Intercellular Communication between Cumulus Cells and Oocytes from Women with PCOS. BioMed Research International. 2020;2020:5403904. https://doi.org/10.1155/2020/5403904
Alam F, Syed H, Amjad S, Baig M, Khan TA, Rehman R. Interplay between oxidative stress, SIRT1, reproductive and metabolic functions. Current Research in Physiology. 2021;4:119-124. https://doi.org/10.1016/j.crphys.2021.03.002
Pal S, Haldar C, Verma R. Photoperiodic modulation of ovarian metabolic, survival, proliferation and gap junction markers in adult golden hamster, Mesocricetus auratus. Comparative Biochemistry and Physiology. Part A, Molecular and Integrative Physiology. 2022; 263:111083. https://doi.org/10.1016/j.cbpa.2021.111083
Zheng B, Meng J, Zhu Y, Ding M, Zhang Y, Zhou J. Melatonin enhances SIRT1 to ameliorate mitochondrial membrane damage by activating PDK1/Akt in granulosa cells of PCOS. Journal of Ovarian Research. 2021;14(1):152. https://doi.org/10.1186/s13048-021-00912-y
Cheng Q, Xu L. FABP5 inhibitor SBFI-26 regulates FOXM1 expression and Wnt signaling pathway in ovarian granulosa cell of patients with polycystic ovary syndrome. Preventive Medicine. 2023; 174:107634. https://doi.org/10.1016/j.ypmed.2023.107634
Hsu HC, Tong S, Zhou Y, Elmes MW, Yan S, Kaczocha M, Deutsch DG, Rizzo RC, Ojima I, Li H. The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites. Biochemistry. 2017;56(27):3454-3462. https://doi.org/10.1021/acs.biochem.7b00194
Chugh RM, Park HS, El Andaloussi A, Elsharoud A, Esfandyari S, Ulin M, Bakir L, Aboalsoud A, Ali M, Ashour D, Igboeli P, Ismail N, McAllister J, Al-Hendy A. Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10. Stem Cell Research and Therapy. 2021;12(1):388. https://doi.org/10.1186/s13287-021-02472-w
Karam M, Najjar H, El Sabban M, Hamade A, Najjar F. Regenerative Medicine for Polycystic Ovary Syndrome: Stem Cell-Based Therapies and Brown Adipose Tissue Activation. Stem Cell Reviews and Reports. 2023;19:853-865. https://doi.org/10.1007/s12015-023-10505-5
Fan XL, Zhang Y, Li X, Fu QL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cellular and Molecular Life Sciences. 2020;77:2771-2794. https://doi.org/10.1007/s00018-020-03454-6
Ullah M, Liu DD, Thakor AS. Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019; 15:421-438. https://doi.org/10.1016/j.isci.2019.05.004
Park HS, Cetin E, Siblini H, Seok J, Alkelani H, Alkhrait S, Liakath Ali F, Mousaei Ghasroldasht M, Beckman A, Al-Hendy A. Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS. International Journal of Molecular Sciences. 2023;24(13):11151. https://doi.org/10.3390/ijms241311151
Maqsood M, Kang M, Wu X, Chen J, Teng L, Qiu L. Adult mesenchymal stem cells and their exosomes: Sources, characteristics, and application in regenerative medicine. Life Sciences. 2020;256: 118002. https://doi.org/10.1016/j.lfs.2020.118002
Ali AT, Guidozzi F. Midlife women’s health consequences associated with polycystic ovary syndrome. Climacteric. 2020;23(2): 116-122. https://doi.org/10.1080/13697137.2019.1679111

Close metadata